Eradication of Prostate Cancer Using F-989

Phase II Eradication of Prostate Cancer Using F-989

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01987999

Enrollment

Registered

2013-11-20

Start date

2013-02-28

Completion date

2015-12-31

Last updated

2019-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.

Interventions

DIETARY_SUPPLEMENTAcetogenins

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of prostate cancer * Referred to the study by their treating physician

Exclusion criteria

\- Any type of treatment before starting study

Design outcomes

Primary

Measure	Time frame	Description
Gleason Score	1 year	A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.

Secondary

Measure	Time frame
Prostate Specific Antigens (PSA)	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026